Eur Rev Med Pharmacol Sci 2018; 22 (9): 2707-2714
DOI: 10.26355/eurrev_201805_14967

Has-MiR-196a-2 is up-regulated and acts as an independent unfavorable prognostic factor in thyroid carcinoma

Y.-T. Fu, D.-Q. Zhang, L. Zhou, S.-J. Li, H. Sun, X.-L. Liu, H.-B. Zheng

Department of Thyroid Surgery, China-Japan Union Hospital of Jilin University, Changchun, China. Haibozheng86@sina.com


OBJECTIVE: To identify the role of hsa-miR-196a-2 in thyroid cancer by bioinformatics analysis.

MATERIALS AND METHODS: The expression profiles of thyroid cancer was download from TCGA. The dysregulated microRNAs were obtained by edger R package. Then, the prognostic data were analyzed by K-M plot. The difference between different groups was analyzed by the t-test. At last, the biological processes of has-miR-196a-2 were obtained with GSEA.

RESULTS: In this study, we found that has-miR-196a-2 was upregulated in thyroid carcinoma by analyzing the TCGA database, which was inversely proportional to the prognosis of patients with thyroid carcinoma. Univariate and multivariate COX analysis showed that has-miR-196a-2 was an independent prognostic risk factor for thyroid carcinoma. Higher expressions of has-miR-196a-2 were found in patients with older age, advanced tumor stage, lymph node metastasis, and local infiltration through the t-test. We found that has-miR-196a-2 was enriched in adherent junction, focal adhesion, and actin cytoskeleton, which are closely related to the invasion and migration of the function pathway. Moreover, it is mainly enriched in tumor progression pathways, such as the PPAR pathway and WNT pathway.

CONCLUSIONS: Hsa-miR-196a-2 is overexpressed in thyroid tumors and is an independent prognostic risk factor for thyroid carcinoma.

Free PDF Download

To cite this article

Y.-T. Fu, D.-Q. Zhang, L. Zhou, S.-J. Li, H. Sun, X.-L. Liu, H.-B. Zheng
Has-MiR-196a-2 is up-regulated and acts as an independent unfavorable prognostic factor in thyroid carcinoma

Eur Rev Med Pharmacol Sci
Year: 2018
Vol. 22 - N. 9
Pages: 2707-2714
DOI: 10.26355/eurrev_201805_14967